CJC-1295
Also known as: CJC-1295 with DAC, Drug Affinity Complex-GHRH, DAC:GRF
A long-acting GHRH analogue that covalently binds to albumin in vivo via a Drug Affinity Complex (DAC), extending its half-life from minutes to over a week.
Overview
CJC-1295 with DAC is a modified GHRH(1-29) analogue engineered with a lysine substitution and a maleimidoproprionic acid (MPA) linker that forms a covalent bond with circulating albumin. This albumin binding dramatically extends its half-life, allowing for infrequent dosing intervals in research protocols. The extended action produces a sustained "bleed" of GH elevation rather than a sharp pulse.
CJC-1295 without DAC (also called Mod GRF 1-29) is a distinct compound with a shorter half-life (~30 minutes) that produces more physiological GH pulses when timed appropriately. Both variants are widely used in research. CJC-1295 with DAC is notable for studies examining the effect of sustained GH elevation on body composition, recovery, and aging biomarkers.
Mechanism of Action
CJC-1295 stimulates GHRH receptors on pituitary somatotrophs. The DAC modification allows covalent binding to albumin's Cys34 residue, creating a circulating depot that slowly releases the active peptide. This results in sustained elevation of GH and subsequently IGF-1 with a once-weekly or twice-weekly dosing profile in research settings.
Research Areas
- ●Long-acting GH secretion models
- ●IGF-1 elevation and anabolic research
- ●Body composition and lean mass
- ●Bone density studies
- ●Recovery and sleep quality research
- ●Combination GHS protocols (with ipamorelin)
Storage & Handling
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 28 days.
Soluble in bacteriostatic water
For Research Use Only. This information is provided for educational and research purposes. CJC-1295 is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.